Tirzepatide
Tirzepatide (GIP/GLP-1 Dual Agonist)
A dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Produces greater weight loss than semaglutide in head-to-head comparisons.
Mechanism of Action
Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic effects on insulin secretion, glucagon suppression, appetite reduction, and fat metabolism.
Health Claims & Evidence
Superior weight loss vs semaglutide
Improves glycemic control in type 2 diabetes
Reduces cardiovascular risk factors
Short-Term Effects
Reduced appetite, nausea during dose escalation, rapid glycemic improvement.
Long-Term Effects
Significant sustained weight loss exceeding most other interventions.
Side Effects
Nausea, vomiting, diarrhea, constipation. Rare: pancreatitis, gallbladder disease.
Contraindications
Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Tirzepatide vs semaglutide for weight loss
Jastreboff et al. · New England Journal of Medicine · 2022
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Tirzepatide and related peptides, and prepare an educational research summary.
Explore Research